travoprost ophthalmic

Action and Spectrum

Drug Interaction

Adverse Reaction

Adverse drug reactions  

Frequency Defined  

>10%  

Ocular hyperemia (35-50%)  

Increased pigmentation of iris  

1-10%  

Abnormal vision (1-4%)  

Decreased visual acuity (5-10%)  

Iris discoloration (1-4%)  

Foreign body sensation (5-10%)  

Pain (5-10%)  

Keratitis (1-4%)  

Blurred vision (1-4%)  

Cataract (1-4%)  

Ocular discomfort (5-10%)  

Pruritus (5-10%)  

Blepharitis (1-4%)  

Conjunctivitis (1-4%)  

Lid margin crusting (1-4%)  

Dry eye (1-4%)  

Photophobia (1-4%)  

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pregnancy warnings:     

AU TGA pregnancy category: B3
US FDA pregnancy category: C 

Lactation: 

Excreted into human milk is unknown 

Pregnancy Categories:       

Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.       

Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women       

Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women       

Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.       

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.       

Category N: There is no data available for the drug under this category 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient Information Leaflet    

Generic Name: travoprost ophthalmic  

Why do we use travoprost ophthalmic? 

travoprost ophthalmic is an Antiglaucoma, Prostaglandin Agonists used to treat Open-Angle Glaucoma.